Antibody development is the entire process of producing and characterizing antibodies. CD ComputaBio is a leading antibody development company, providing computing-based antibody development services. With our computing platform, we are ready to help you deal with the most difficult research challenges. If you have any needs in this regard, you can contact us at any time.
Computational biology can find solutions faster and more accurately, thereby reducing the high cost of drug development. CD ComputaBio implements computationally driven solutions to develop therapeutic antibodies, as biopharmaceuticals are used in more and more pathologies, including oncology. The goal of CD ComputaBio is to propose a calculation-based antibody development solution that reduces the risk of failure and the duration of preclinical steps to meet the needs of scientific researchers.
The computational antibody development platform usually includes the following services:
At present, the commonly used computational antibody design platforms are mainly Discovery Studio and Rosetta developed from protein structure simulation, and Schrdinger developed from chemical drug structure simulation.
|Project name||Antibody development|
|Our services||CD ComputaBio offers antibody development service to meet the specific needs of different customers.|
|Timeline||Decide according to your needs.|
|Deliverable||We provide you with raw data and prediction results.|
CD ComputaBio provides professional antibody development service to meet the specific needs of regular customers on time and according to budget. CD ComputaBio relies on world-class technical expertise, we provide customers with the best quality one-stop antibody development service, including the development of scientific procedures according to different solution needs. Please feel free to contact us for more detailed information, our scientists will tailor the most reasonable plan for your project. If you want to know more service prices or technical details, please feel free to contact us.